InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,330.02
(
-0.88%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jellybean

Send PM Follow Ignore
Followers 10
Posts 1097
Boards Moderated 0
Alias Born 08/23/2004

jellybean

Re: dewophile post# 81124

Thursday, 07/23/2009 6:49:41 PM

Thursday, July 23, 2009 6:49:41 PM

Post# of 251715
If these statements are correct:

1. Atacicept is a receptor fragment that binds both blys and April, and acts as a sink to remove both proteins from circulation.

2. LympostatB or belimumab is an antibody to binds to blys and, presumably, removes it from circulation.

Can you explain how those different mechanisms result in one compound inhibiting the BCMA receptors and blys/br3 pathway while the other does not?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up